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The susceptibility of 11 clinical isolates of Mycobacterium tuberculosis, 3 
M. kansasii, 3 M. xenopi, 2 M. scrofulaceum, 2 M. marinum, 2 M. malmoense to 
fleroxacin, ciprofloxacin, norfloxacin, rifampicin, isoniazid, ethambutol, and 
streptomycin was determined by the standard proportion method (Middlebrook 
7HlO agar). All M. tuberculosis, M. kansasii, M. xenopi, M. scrofulaceum, M. 
marinum, and M, malmoense isolates including those resistant to conventional 
antimycobacterials were inhibited by O· 5 mg/l of fleroxacin and ciprofloxacin, the 
lowest tested concentration. Fleroxacin and ciprofloxacin along with ofloxacin, 
pefloxacin, ansamycin, clofazimine and cycloserine were also tested against 14 
isolates of the M. avium complex. Nine of 14 strains (64%) of the M. avium 
complex were found susceptible to 4 mg/l of fleroxacin and a similar percentage to 
the other quinolones. On the basis of its in-vitro potency and its favourable 
pharmacokinetic properties fleroxacin appears to be sufficiently active to warrant 
further experimental trials against difficult to treat mycobacteria. 
Introduction 
Fleroxacin (Ro 23-6240, AM-833), the 6,8 difluoro-l-(2-fluoroethyl)-1,4-dihydro-
7-(4-methyl-l-piperazinyl)-4-oxo-quinoline-3-carboxylic acid has been shown to be 
highly active against a broad spectrum of Gram-positive and Gram-negative aerobic 
micro-organisms with the exception of many streptococci and anaerobes (Chin, 
Brittain & Neu, 1986). However, the antimycobacterial activity of this newly 
discovered 6-fluoroquinolone has not been as well characterized as other sectors of its 
antibacterial spectrum. 
The purpose of the present study was to determine the in-vitro activity of fleroxacin 
in comparison with ciprofloxacin and norfloxacin against selected strains of susceptible 
and multiply resistant Mycobacterium tuberculosis, and against unselected isolates of 
the M. avium complex and of a further ~ix clinically important species of mycobacteria 
other than tubercle bacilli (MOTT). Concurrently, the susceptibility of the strains 
belonging to the M. avium complex was also determined to ofloxacin, pefloxacin, 
ansamycin, clofazimine and D-cycloserine, and that of all the other mycobacteria 
mentioned to the first-line antituberculous compounds. 
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Materials and methods 
Antimicrobial drugs 
The following compounds were provided as standard laboratory powders by the listed 
suppliers: fieroxacin [Ro 23-6240; AM-833 (F. Hoffmann-La Roche & Co. Ltd., Basle, 
Switzerland)]; ansamycin [(LM-427, a spiropiperidyl rifamycin); Farmitalia Carlo 
Erba, Milan, Italy]; ciprofioxacin (Bayer AG, Wuppertal West Germany); clofazimine 
(Ciba-Geigy, Basle, Switzerland); and D-cycloserine (F. Hoffmann-La Roche & Co. 
Ltd., Basle, Switzerland). Pefioxacin (Laboratoires Roger Bellon, Neuilly-s.-Seine, 
France), ofioxacin (Hoechst AG, Frankfurt a. Main, West Germany), norfioxacin 
(Merck, Sharp & Dohme, West Point, PA, USA) as well as rifampicin, streptomycin, 
ethambutol, and D-cycloserine were obtained from commercial sources. 
Isolates 
Thirty seven isolates (11 M. tuberculosis, 14 M. avium complex, 3 M. kansasii, 3 
M. xenopi, 2 M. scrofulaceum, 2 M. malmoense, 2 M. marinum) were studied. All 
organisms were drawn from the stock culture collection of recent clinical isolates of the 
Department of Medical Microbiology of the University of Zurich except for those 
provided by Dr P. A. Jenkins, PHLS Mycobacterium Reference Unit, University 
Hospital of Wales, Cardiff, UK (3 strains of M. avium complex) and Dr K. H. 
Schroeder, Forschungsinstitut Borstel, West Germany (2 M. avium complex). The 
strains were identified by standard methods (Sommers & Good, 1985) and kept on 
Lowenstein-Jensen slants up to the time of use. Of the 11 strains of M. tuberculosis, 6 
were susceptible and 5 resistant to both isoniazid and rifampicin. Of the 5 resistant 
isolates, 3 were also resistant to ethambutol and 2 to streptomycin. M. tuberculosis 
H37Rv was used as the control strain throughout the trial. 
Susceptibility testing 
Susceptibility testing was performed by the proportion method (Vestal, 1981; 
Sommers & Good, 1985; McClatchy, 1986). In brief, fieroxacin, ciprofioxacin, 
ofioxacin and norfioxacin were each solubilized in 0·06 ml of 1 N NaOH and 1 ml of 
methanol and, along with pefioxacin and D-cycloserine, diluted in sterile water to the 
desired final concentration. In contrast, ansamycin was dissolved III 
dimethylformamide and diluted in Sorensen buffer (pH 6·8), and clofazimine in 
absolute ethanol, respectively. Compounds were adjusted for solvent, water and 
impurity content. 
Fresh solutions of the antibacterial agents were prepared on the day of the 
experiment, filter sterilized (0·22 11m Millipore) and, in the case of fieroxacin, stored in 
the dark up to the time of use. Appropriately concentrated aliquots (0·25 ml) of each 
drug were placed in three of four quadrants of each plate (the remaining quadrant 
being the antimicrobial-free control sector) and mixed with cooled molten (52°C) agar 
[Middlebrook 7HIO agar (Difco Laboratories, Detroit, MI, USA) containing 10% 
(v/v) Middlebrook OADC supplement (Difco)]. The final volume was 5 ml per 
quadrant (85 mm Petri dish), and final concentrations of antimicrobials tested were 
0'5, 2 and 8 mg/l for the 6-fiuoroquinolones against M. tuberculosis and most MOTT, 
and 2, 4, and 8 mg/l against the M. avium complex. Other final concentrations 
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employed were 2 mg/l for ansamycin and streptomycin, 1 mg/l for clofazimine, 
rifampicin and isoniazid, 10 mg/l for ethambutol, and 30 and 60 mg/l for D-cycloserine. 
In preparation for inoculation mycobacteria were grown in Middlebrook 7H9 broth 
supplemented with Middlebrook OADC enrichment (Difco) at 37°C for five days, 
days, then diluted with saline and matched to a McFarland No. 1 standard. The 
resulting suspension was carefully vortexed for optimal homogenization prior to two 
consecutive 1 : 20 dilutions. Aliquots (150 /ll per quadrant) from each of these three 
successive dilutions were used to seed the entire series of test plates set up for a 
particular strain including growth controls. Likewise, aliquots from the respective 
series of bacterial suspensions were used to demonstrate on other control plates that 
the solvents at the concentrations used in the trial were not inhibitory to the 
mycobacteria tested. 
Cultures were incubated at 37°C in air with 5 to 10% CO2 (except for M. marinum 
kept at 30°C in room air). Plates were read after three weeks' incubation with a 
stereomicroscope. Drug activity was assessed by dividing the number of colony 
forming units on quadrants with antimycobacterial by that of the respective drug-free 
control quadrant on the same plate growing preferentially 200-700 colonies. 
Inhibitory activity of the test compounds was defined as the lowest concentration of 
antimycobacterial that reduced the colony count to less than 1 % of that observed on 
the antimicrobial-free quadrant. Conversely, mycobacterial growth of 1 % or greater 
on the plate with the highest listed or with the only stated concentration of 
antimycobacterial compound was interpreted as full resistance, and growth at the 
lower of two stated clinically achievable concentrations as partial resistance to a given 
compound. 
Stability of fleroxacin in Middlebrook 7H9 broth (Difco, Lot. No. 673876) and 
0·2% glycerol (Merck B 42522) was determined by high-performance liquid 
chromatography with a fluorimetric detector (SMF, Kontron) using 0·15% sodium 
dodecyl sulphate in acetonitrile-water-buffer pH 2 (Titrisol, Merck) as mobile phase 
for both the precolumn (Pellicular ODS®, 40/lm, Whatman) and the column 
(Novapack®, 4/lm; 150 x 3·9 mm ID, Waters). Aliquots of broth were removed from 
incubation at 37°C in the dark (fleroxacin being susceptible to degradation by light 
after exposure over several days) and sampled on days 0, 7, and 28. The coefficient of 
variation of our assay system was less than 5%. 
Results 
Stability 
Experiments revealed that the potency of fleroxacin (10 mg/l) was fully maintained in 
the dark at 4°C in 0·9% sodium chloride and in 4% reconstituted human albumin over 
a four week storage period (data not shown). In experiments with Middlebrook 7H9 
broth storage at 37°C with or without 0·025 mg % malachite green, the potency of 
fleroxacin degraded by 23% without and by 25% with malachite green over a 28 day 
period (data not shown). 
Antimycobacterial activity 
Results on the activity of fleroxacin and six comparative compounds against 
M. tuberculosis (with some strains being resistant to both rifampicin and isoniazid) 
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and five MOTT species other than M. avium complex are summarized (Table I). All 23 
strains, including the control strain H37Rv, were found to be susceptible to fleroxacin 
and ciprofloxacin at 0·5 mg/l, the lowest concentration tested. In contrast, only 16 
(70%) of 23 tested isolates were susceptible to norfloxacin at 0·5 mg/l even though 
100% of strains were inhibited by a concentration of 2 mg/l. Thus, norfloxacin was less 
potent (W /W) than the other quinolones against M. tuberculosis, M. kansasii, 
M. scrofulaceum and M. malmoense. As expected, rifampicin and isoniazid were inactive 
at the tested concentrations against multi-resistant M. tuberculosis even though the 
latter were quinolone-susceptible. Isoniazid, but not rifampicin, was inactive also against 
most MOTT strains examined. 
Some of the 14 strains of the M. avium complex were partially resistant to the 
6-fluoroquinolones. The activity of fleroxacin as measured was similar to that of 
ciprofloxacin, norfloxacin and ofloxacin but slightly weaker than that of pefloxacin 
(Table II). At concentrations of 4 mg/l and 8 mg/l 64% and 79% of tested isolates 
were susceptible to fleroxacin and ciprofloxacin as against 71 % and 93% to pefloxacin. 
All isolates resistant to 8 mg/l of fleroxacin were also resistant to 8 mg/l of 
ciprofloxacin, norfloxacin, and ofloxacin. One strain was even uniformly resistant to all 
five quinolones at the highest tested concentration of 8 mg/l. 
Table II. Activity of fleroxacin and seven comparative compounds 
against M. avium complex (14 strains) 
Concentration Number Strains· 
Drug (mg/I) susceptible % 
Fleroxacin 2 6 43 
4 9 64 
8 II 79 
Ciprofloxacin 2 7 50 
4 9 64 
8 II 79 
Norfloxacin 2 4 29 
4 7 50 
8 11 79 
Ofloxacin 2 4 29 
4 8 57 
8 II 79 
Pefloxacin 2 6 43 
4 10 71 
8 l3 93 
Ansamycin 2 14 100 
Clofazimine 12 86 
Cycloserine 30 10 71 
60 14 100 
·Susceptible, determined by the proportion method (Canetti) on Middlebrook 
7HIO agar. 
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Interestingly, the quinolone resistant strains of the M. avium complex were mainly 
susceptible in-vitro to the three non-quinolone drugs, and conversely, the two 
clofazimine resistant (MIC > I mg/I) isolates as well as the four D-cycloserine resistant 
(MIC > 30 mgfl) strains of the M. avium complex were inhibited by all quinolones 
tested and by ansamycin. D-cycloserine was inhibitory to ten strains of the M. avium 
complex at a concentration of 30 mg/l and to all 14 strains at a concentration of 
60 mg/I (peak serum level of D-cycloserine 20-50 mg/l). Similarly, 2 mg/I of ansamycin, 
a congener of rifamycin-S, were inhibitory in vitro to all M. avium complex isolates 
included in the trial. 
Discussion 
There still is an urgent need for new drugs to improve the prognosis of patients 
suffering from mycobacterial diseases due to drug-resistant M. tuberculosis or non-
tuberculous mycobacteria. Cure rates of infections due to multiresistant 
M. tuberculosis (Costello, Caras & Snider, 1980; Bass, 1986; Jones et al., 1987) and 
drug resistant MOTT have remained unsatisfactory despite combination therapy 
(Greene et al., 1982; Masur et al., 1987). Because of the recently discovered high 
incidence of mycobacterial infections in patients with AIDS (Goldman, 1987), there is 
an increasing demand for new first-line antimycobacterial agents that cure even the 
most severe forms of opportunistic M. avium complex infections in patients afflicted 
with the HI V-induced immunodeficiency (Horsburgh et al., 1986), and of other 
mycobacterial diseases that are refractory to currently used antimycobacterial drugs as 
well. 
The present study describes the in-vitro activity of the new 6-ftuoroquinolone 
fteroxacin in comparison to that of ciproftoxacin, norftoxacin and other drugs against 
some very difficult to treat mycobacteria. In these susceptibility determinations, which 
were limited to antibacterial concentrations near or at the (proposed) susceptibility 
breakpoints of the various quinolones under study (Wise et al., 1986, 1987), fteroxacin 
showed virtually the same degree of in-vitro activity (w/w) as ciproftoxacin against 
multiply resistant M. tuberculosis and six species of MOTT other than M. avium 
complex. 
Fenlon & Cynamon (1986) found that the MIC90 of ciproftoxacin and norftoxacin 
were 0·5 and 4 mg/I for M. tuberculosis isolates, respectively. Thus, there was good 
agreement between their study and our results. Using 7Hl1 Middlebrook agar, Gay, 
DeYoung & Roberts (1984) and Berlin, Young & Bruckner (1987) reported somewhat 
higher MICs for ciproftoxacin (MIC9o of 1 mg/I) and norftoxacin and ciproftoxacin 
(MIC9o of 8 and 2·0 mg/I, respectively) against M. tuberculosis. Collins & Uttley 
(1985) reporting on the activities of ciproftoxacin against M. tuberculosis and its 
geographical variants, M. xenopi, M. marinum, M. kansasii, and M. avium-
intracellulare-scrofulaceum, published that 164 out of 207 isolates (all except M. avium-
intracellulare-scrofulaceum) had ciproftoxacin MICs of 1·56 mg/l or less in Lowenstein-
Jensen medium. These values were somewhat higher than those observed by us. 
Methodological differences between the laboratories and varying susceptibility in 
different strains may account for the three-fold disparity in MICs. In the present study, 
two strains of M. malmoense were found susceptible to 0·5 mg/l of fteroxacin and 
ciproftoxacin, whereas others (Davies, Sparham & Spencer, 1987) have reported lower 
activity (MIC of 5 mg/l or greater) for ciproftoxacin against these organisms. 
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The results of f1eroxacin and ciprofloxacin against 14 isolates of M. avium complex 
agreed well with those of Gay et al. (1984) who reported on the activity of 
ciprofloxacin (MIC9o at 16 mg/l) and of norfloxacin (MIC9o > 16 mg/l) against these 
organisms. Fenlon and Cynamon (1986) found lower MICs to ciprofloxacin (MIC9o 
2 mg/l) and to ofloxacin (MIC9o 8 mg/l) for M. intracelluiare than our study. The 
observation of Tsukamura (1983) might explain the discrepancy. This author found 
that M. intracelluiare was inhibited by lower concentrations of ofloxacin than 
M. avium. The reason for the divergence in activity of ofloxacin against the two 
species, M. avium or M. intracelluiare, could account for correspondingly diverging 
activity of other quinolones. Yet irrespective of whether the choice of strains could 
have influenced the results in favour of the compounds, ofloxacin did not quite match 
the activity (w/w) of ciprofloxacin in Fenlon & Cynamon's study (1986) nor that of 
ciprofloxacin and f1eroxacin in the present study. Pefloxacin was also active in the 
present trial against M. avium complex. We are unaware that this finding has been 
reported to date in the literature. Whether the pefloxacin activity would be confirmed 
in the clinical situation where the drug undergoes metabolism (Wise et ai., 1987) 
remains to be proven. 
Heifets & Iseman (1985) tested 523 isolates of M. avium complex and found that 
95% were susceptible to 2 mg/l of ansamycin. The MIC90 for 20 M. intracelluiare 
isolates was I mg/l of ansamycin in the series reported by Cynamon (1985) and 2 mg/l 
in that published by Kiehn et al. (1985). In addition, the 35 isolates of Kiehn et ai. 
(1985) were susceptible to cycloserine (30 and 60 mg/l) and clofazimine (1 mg/l). Our 
data agreed generally with these results but unlike these authors we encountered two 
strains resistant to clofazimine (1 mg/I) and four strains resistant to D-cycloserine 
(30 mg/l). The proven clinical results with ansamycin and clofazimine singly or in 
combination against M. avium infections (Whimbey, Kiehn & Armstrong, 1986) and 
the promising in-vitro activity of fleroxacin and the other new 6-f1uoroquinolones raise 
the hope that with the advent of these new compounds the future of patients afflicted 
with M. avium complex infection could be less troublesome than at present. 
Fleroxacin with its bioavailability of 100% after oral absorption (tablet), a low degree 
of metabolism and a long plasma elimination half-life of 9-10 h (Weidekamm, 
et ai., 1987) is known to combine not only a wide spectrum of activity similar to that 
of its congeners but also promising pharmacokinetics that distinguish it from the 
earlier quinolones such as the ones used comparatively in this trial (Wise et ai., 1986, 
1987). Its rapid and uniform penetration into blister fluid in volunteers with peak levels 
in excess of 3 mg/l following a standard 400 mg oral dose suggests that some of the 
pathogenic mycobacteria tested might respond to the compound and that the 
compound is worth further experimental investigations against these organisms 
including killing tests (Yajko, Nassos & Hadley, 1987). 
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